Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR -Mutated NSCLC
ConclusionsPre-treatmentEGFR copy number gain determined by amplicon-based next generation sequencing data predicts worse overall survival inEGFR-mutated patients treated with first-line EGFR-tyrosine kinase inhibitors. T790M at relapse and subsequent treatment with osimertinib predict longer overall survival. (Source: Targeted Oncology)
Source: Targeted Oncology - February 19, 2021 Category: Cancer & Oncology Source Type: research

BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?
AbstractBackgroundB-Raf proto-oncogene (BRAF)-V600E mutations (BRAFmt) in colorectal cancer (CRC) predominantly occur in right-side (RS) primaries. In metastatic CRC (mCRC), there is substantial overlap between the reported features of BRAFmt and of an RS primary.ObjectivesTo explore the significance of BRAFmt in a left-side (LS) primary, we analysed data from a multi-site mCRC registry. Tumours distal to the splenic flexure were considered LS.ResultsOf 3380 patients enrolled from June 2009 to June 2020, 214 (13%) of 1657 with known status were BRAFmt: 127 (24%) of 524 RS and 87 (8%) of 1133 LS. LS versus RS BRAFmt were yo...
Source: Targeted Oncology - February 18, 2021 Category: Cancer & Oncology Source Type: research

Utility of Cerebrospinal Fluid Cell-Free DNA in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis
ConclusionsFor patients with EGFR-mutant NSCLC with LM, CSF supernatant is a valuable source for EGFR mutation testing and may provide important information. (Source: Targeted Oncology)
Source: Targeted Oncology - February 10, 2021 Category: Cancer & Oncology Source Type: research

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
This study investigated the ability of lactate dehydrogenase (LDH) and S100 calcium-binding protein B (S100B) to detect response and disease progression during treatment with BRAFi.Patients and MethodsBaseline levels of LDH and S100B and repeated measurements during therapy were recorded retrospectively in 191 patients with metastatic melanoma. LDH and S100B levels were compared between distinct time points (baseline, first follow-up visit [FV], best objective response [BR], and progressive disease [PD]). The prognostic ability of the serum biomarkers in relation to disease-specific survival (DSS) was assessed with univari...
Source: Targeted Oncology - February 8, 2021 Category: Cancer & Oncology Source Type: research

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study
ConclusionsFirst-line osimertinib treatment resulted in a clinically meaningful PFS and OS benefit versus comparator EGFR TKI in Chinese patients with EGFRm advanced NSCLC. Safety data were consistent with the known safety profile of osimertinib.Clinical Trial RegistrationClinicalTrials.gov NCT02296125, registered 20 November 2014 (Source: Targeted Oncology)
Source: Targeted Oncology - February 5, 2021 Category: Cancer & Oncology Source Type: research

The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma
AbstractHepatocellular carcinoma (HCC) is one of the most common cancers and a main cause of cancer-associated death worldwide. Even with the successful launch of sorafenib for the clinical treatment of HCC in 2007, the long-term survival for patients with HCC is still suboptimal, largely due to the occurrence of primary or acquired drug resistance. With an improved understanding of the molecular pathophysiology and tumor heterogeneity of HCC, therapeutic options have been evolving rapidly in recent years. While lenvatinib, cabozantinib, regorafenib, and the monoclonal antibody ramucirumab, as well as the immune checkpoint...
Source: Targeted Oncology - February 2, 2021 Category: Cancer & Oncology Source Type: research

Vaccine Therapies for Cancer: Then and Now
AbstractThere are strong biologic and preclinical rationales for the development of therapeutic cancer vaccines; however, the clinical translation of this treatment strategy has been challenging. It is now understood that many previous clinical trials of cancer vaccines used target antigens or vaccine designs that inherently lacked sufficient immunogenicity to induce clinical responses. Despite the historical track record, breakthrough advances in cancer immunobiology and vaccine technologies have supported continued interest in therapeutic cancer vaccinations, with the hope that next-generation vaccine strategies will ena...
Source: Targeted Oncology - January 29, 2021 Category: Cancer & Oncology Source Type: research

A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers
ConclusionsAbemaciclib was well tolerated and the safety and PK profiles in Chinese patients were comparable to those previously reported in non-Chinese populations. Preliminary antitumor activity was observed.ClinicalTrials.gov identifierNCT02919696. (Source: Targeted Oncology)
Source: Targeted Oncology - January 25, 2021 Category: Cancer & Oncology Source Type: research

Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab
ConclusionsThe development of irAEs might be associated with survival outcomes with nivolumab treatment in patients with  AGC. (Source: Targeted Oncology)
Source: Targeted Oncology - January 21, 2021 Category: Cancer & Oncology Source Type: research

Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib
ConclusionsThe combined analysis of these studies confirms the objective tumor responses and improvements in PFS observed in the initial phase III trial, providing further support for the clinical benefit of sunitinib in patients with advanced panNETs.ClinicalTrials.gov IdentifiersNCT00428597 and NCT01525550. (Source: Targeted Oncology)
Source: Targeted Oncology - January 7, 2021 Category: Cancer & Oncology Source Type: research

Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma
ConclusionsLifetime smoking exposure plays a significant role in the effectiveness of pembrolizumab in patients with metastatic UC. (Source: Targeted Oncology)
Source: Targeted Oncology - January 5, 2021 Category: Cancer & Oncology Source Type: research

Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers
ConclusionsThe majority of uterine and ovarian cancers (93%) did not have molecular alterations with corresponding Food and Drug Administration-approved treatments. Even in patients with a potentially actionable alteration, gynecologic oncologists were more likely to choose an alternative therapy. Further investigation is warranted to determine which patients with uterine and ovarian cancer are most likely to benefit from molecular tumor profiling and the ideal timing of testing. The potential to identify effective therapeutic options in a minority of patients needs to be balanced with the current limited clinical applicab...
Source: Targeted Oncology - January 5, 2021 Category: Cancer & Oncology Source Type: research

Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective
AbstractPROteolysis Targeting Chimeras (PROTACs) are a family of heterobifunctional small molecules that specifically target cellular proteins for degradation. Given that their mode of action is distinct from that of small-molecule inhibitors widely used in clinical practice, PROTACs have the potential to improve current cancer therapies. Multiple studies have suggested that PROTACs exhibit enhanced pharmacodynamics and reduced toxicity both in vitro and in vivo compared to clinically relevant small-molecule kinase inhibitors. In addition, PROTACs have been reported to be less prone to mutation-mediated drug resistance in ...
Source: Targeted Oncology - December 28, 2020 Category: Cancer & Oncology Source Type: research

Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
ConclusionsThe maximum tolerated dose of rucaparib is 500 mg twice daily when co-administered with bevacizumab. The plasma concentration –time profiles of rucaparib in combination with bevacizumab suggest no pharmacokinetic interactions between the drugs. The randomized phase II portion of MITO 25 will further investigate rucaparib maintenance treatment with or without bevacizumab in patients with newly diagnosed stage III–IV ova rian cancer who responded to carboplatin-paclitaxel chemotherapy with or without bevacizumab.Trial RegistrationClinicalTrials.gov identifier NCT03462212; registered March 2018. (Source: Targeted Oncology)
Source: Targeted Oncology - December 28, 2020 Category: Cancer & Oncology Source Type: research

Correction to: SB8: A Bevacizumab Biosimilar
The article SB8: A Bevacizumab Biosimilar, written by Yahiya Y. Syed, was originally published (Source: Targeted Oncology)
Source: Targeted Oncology - December 11, 2020 Category: Cancer & Oncology Source Type: research

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA
ConclusionsIn this real-world study, adult cHL patients initiated on pembrolizumab had significantly lower rates of all-cause and cHL-related hospitalizations compared to patients initiated on nivolumab. (Source: Targeted Oncology)
Source: Targeted Oncology - December 7, 2020 Category: Cancer & Oncology Source Type: research

The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib
AbstractBackgroundThe allele frequency of epidermal growth factor receptor (EGFR) mutations could be a potential molecular biomarker for the outcome of osimertinib therapy.ObjectiveThe purpose of our study was to assess the clinical relevance of the allele frequency ofEGFR mutations in plasma-based circulating tumor DNA (ctDNA) before starting osimertinib therapy in patients with advancedEGFR-mutated non-small cell lung cancer (NSCLC) who had progressed under treatment with EGFR tyrosine kinase inhibitors (TKIs).Patients and MethodsWe enrolled 141 patients with advancedEGFR T790M-positive NSCLC who underwent second-line os...
Source: Targeted Oncology - December 3, 2020 Category: Cancer & Oncology Source Type: research

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
AbstractOral darolutamide (Nubeqa ™) is a novel second-generation, nonsteroidal, selective androgen receptor (AR) inhibitor indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). In the pivotal multinational, phase 3 ARAMIS trial in men with nmCRPC, relative to placebo plus ongoing androgen de privation therapy (ADT), darolutamide (+ ADT) significantly prolonged metastasis-free survival (MFS) at the time of the primary analysis and overall survival (OS) at the time of the final OS analysis and was generally well tolerated in extended follow-up. Albeit long-term data from the real...
Source: Targeted Oncology - November 25, 2020 Category: Cancer & Oncology Source Type: research

Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis
AbstractBackgroundThe prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in patients with cancer has been inconsistent across previous studies.ObjectiveThis meta-analysis aimed to investigate the prognostic significance of sPD-L1 in human tumors.MethodsA comprehensive search of PubMed, Web of Science, Embase, and Cochrane databases from inception to January 6, 2020 was conducted. Studies of sPD-L1 measured by enzyme-linked immunosorbent assay (ELISA) that had available hazard ratios (HRs) for survival outcomes based on high or low sPD-L1 levels were included. The primary endpoint was long-term survival, na...
Source: Targeted Oncology - November 22, 2020 Category: Cancer & Oncology Source Type: research

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
ConclusionResults from this phase I study indicate that pimasertib has clinical activity in patients with locally advanced/metastatic melanoma, particularlyBRAF- andNRAS-mutated tumors, at clinically relevant doses associated with pERK inhibition in peripheral blood mononuclear cells.Trial RegistrationClinicalTrials.gov, NCT00982865 (Source: Targeted Oncology)
Source: Targeted Oncology - November 19, 2020 Category: Cancer & Oncology Source Type: research

Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
ConclusionsThis analysis suggests that palbociclib exposure has no impact on PFS when the dose reduction algorithm from palbociclib clinical trials is used. There is no difference in efficacy between Asians and non-Asians, despite the higher level of dose reductions in Asians.PfizerNCT01740427. (Source: Targeted Oncology)
Source: Targeted Oncology - November 19, 2020 Category: Cancer & Oncology Source Type: research

SB8: A Bevacizumab Biosimilar
AbstractSB8 is a biosimilar of the monoclonal anti-VEGF antibody bevacizumab and is approved in the EU for use in the same types of cancer as bevacizumab. SB8 has similar physicochemical and pharmacodynamic properties to those of reference bevacizumab and pharmacokinetic equivalence was shown in healthy volunteers and patients with non-small cell lung cancer (NSCLC). SB8 demonstrated equivalent clinical efficacy to reference bevacizumab in patients with metastatic or recurrent nonsquamous NSCLC, with similar tolerability, safety and immunogenicity profiles. (Source: Targeted Oncology)
Source: Targeted Oncology - November 18, 2020 Category: Cancer & Oncology Source Type: research

Acknowledgement to Referees
(Source: Targeted Oncology)
Source: Targeted Oncology - November 17, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product
Discussion, right column, second paragraph. (Source: Targeted Oncology)
Source: Targeted Oncology - November 12, 2020 Category: Cancer & Oncology Source Type: research

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
ConclusionsBased on the safety profile and efficacy signals, a continuous bid regimen was the preferred dosing schedule and the RP2D was defined as 60 mg bid.Trial RegistrationClinicalTrials.gov, NCT00982865. (Source: Targeted Oncology)
Source: Targeted Oncology - November 10, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE ‑2 Study
The listing of the author names and affiliations, which previously read. (Source: Targeted Oncology)
Source: Targeted Oncology - November 10, 2020 Category: Cancer & Oncology Source Type: research

Developing Symptom Lists for People with Cancer Treated with Targeted Therapies
ConclusionsSymptom lists should be created based on input from patients. The item set described will be applicable to the assessment of new TTs, and in monitoring treatment. (Source: Targeted Oncology)
Source: Targeted Oncology - November 9, 2020 Category: Cancer & Oncology Source Type: research

Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis
ConclusionsEverolimus reduces the risk of disease progression in hormone receptor (+) MBC. In patients with HER2 (+) disease, the benefit is limited for those with hormone receptor ( −) disease. Given the approval and use of newer drugs in MBC, clinical trials and real-world data are needed to confirm the benefit of everolimus and define the best treatment sequence strategy to adopt in that setting. (Source: Targeted Oncology)
Source: Targeted Oncology - November 5, 2020 Category: Cancer & Oncology Source Type: research

A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping
ConclusionsOur tailored next-generation sequencing assay coupled with a comprehensive analysis may improve therapeutic management in a significant number of patients with melanoma. Updating such a panel and implementing multi-omic approaches will further enhance patients ’ clinical management. (Source: Targeted Oncology)
Source: Targeted Oncology - November 5, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
An Online First version of this article was made available online athttps://link.springer.com/article/10.1007/s11523-020-00757-3 on 12 October 2020. Errors were subsequently identified in the article, and the following corrections should be noted. (Source: Targeted Oncology)
Source: Targeted Oncology - October 28, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer
The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (Source: Targeted Oncology)
Source: Targeted Oncology - October 27, 2020 Category: Cancer & Oncology Source Type: research

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
ConclusionsCetuximab does not have clinical activity in patients with advanced BC, NSCLC, and OC withoutKRAS, NRAS, or BRAF mutations.Clinical Trial RegistrationNCT02693535 (26 February, 2016). (Source: Targeted Oncology)
Source: Targeted Oncology - October 22, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Biologic Drug Quality Assurance to Optimize HER2+  Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3
The article Biologic Drug Quality Assurance to Optimize HER2+  Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3, (Source: Targeted Oncology)
Source: Targeted Oncology - October 20, 2020 Category: Cancer & Oncology Source Type: research

Targeting Nuclear Export Proteins in Multiple Myeloma Therapy
AbstractMultiple myeloma (MM) is an incurable malignancy of plasma cells with a clinical course characterized by multiple relapses and treatment refractoriness. While recent treatment advancements have extended overall survival (OS), refractory MM has a poor prognosis, with a median OS of between 4 and 6 months. Nuclear export inhibition, specifically inhibition of CRM1/XPO1, is an emerging novel treatment modality that has shown promise in treatment-refractory MM. Initially discovered in yeast in 1983, early clinical applications were met with significant toxicities that limited their utility. The creation of small molecu...
Source: Targeted Oncology - October 19, 2020 Category: Cancer & Oncology Source Type: research

Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry
ConclusionsAnti-EGFR rechallenge provides clinical benefit in patients withRAS wild-type metastatic CRC. (Source: Targeted Oncology)
Source: Targeted Oncology - October 17, 2020 Category: Cancer & Oncology Source Type: research

Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT - 3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
ConclusionsMonotherapy with sunitinib does not have clinical activity in patients with mCRC withFLT-3 amplification and should not be prescribed for off-label use. Other treatments should be considered for these patients, including treatments offered in clinical trials.Clinical Trial registrationNCT02693535 (26 February 2016). (Source: Targeted Oncology)
Source: Targeted Oncology - October 17, 2020 Category: Cancer & Oncology Source Type: research

Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data
AbstractGenomic instability is one of the hallmarks of cancer. The incidence of genetic alterations in homologous recombination repair genes increases during cancer progression, and 20% of prostate cancers (PCas) have defects in DNA repair genes. Several somatic and germline gene alterations drive prostate cancer tumorigenesis, and the most important of these areBRCA2,BRCA1,ATM andCHEK2. There is a group of BRCAness tumours that share phenotypic and genotypic properties with classicalBRCA-mutated tumours. Poly(ADP-ribose) polymerase inhibitors (PARPis) show synthetic lethality in cancer cells with impaired homologous recom...
Source: Targeted Oncology - October 12, 2020 Category: Cancer & Oncology Source Type: research

Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product
ConclusionsThese results support a conclusion of similar clinical efficacy between ABP 798 and rituximab RP in patients with follicular lymphoma.NCT NumberNCT02747043; first posted April 21, 2016.EudraCT Number2013-005,542-11; submitted 14 October, 2014. (Source: Targeted Oncology)
Source: Targeted Oncology - October 12, 2020 Category: Cancer & Oncology Source Type: research

Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
The objective of this study was to analyse the prognostic role of the baseline eosinophil count in patients with sorafenib-treated hepatocellular carcinoma.Patients and MethodsA training cohort of 92 patients with advanced- or intermediate-stage sorafenib-treated hepatocellular carcinoma and two validation cohorts of 65 and 180 patients were analysed. Overall survival and progression-free survival in relation to baseline eosinophil counts were estimated by the Kaplan –Meier method. Univariate and multivariate analyses were performed.ResultsA negative prognostic impact of low baseline eosinophil counts (
Source: Targeted Oncology - October 12, 2020 Category: Cancer & Oncology Source Type: research

Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan
AbstractBackgroundEnzalutamide is a novel, non-steroidal anti-androgen that has demonstrated excellent anti-tumor activity for both non-metastatic and metastatic castration-resistant prostate cancer (nmCRPC and mCRPC) patients, and that is being rapidly introduced into clinical practice in Japan.ObjectiveWe retrospectively investigated the treatment efficacy, safety profile, and prognostic factors of enzalutamide over a relatively long observation period in Japanese patients with nmCRPC and mCRPC.Patients and methodsThe medical records of 184 consecutive Japanese patients with nmCRPC and mCRPC who started enzalutamide trea...
Source: Targeted Oncology - October 10, 2020 Category: Cancer & Oncology Source Type: research

Small Molecule Destabilizer of β-Catenin and Ras Proteins Antagonizes Growth of K-Ras Mutation-Driven Colorectal Cancers Resistant to EGFR Inhibitors
ConclusionsCPD0857 may be a potential drug for treating aggressive CRC carrying mutations that aberrantly activate Wnt/ β-catenin and Ras-ERK pathways. (Source: Targeted Oncology)
Source: Targeted Oncology - October 6, 2020 Category: Cancer & Oncology Source Type: research

Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)
ConclusionDespite the good tolerance, palbociclib monotherapy did not show favorable efficacy against recurrent AO.Trial RegistrationThis study is registered with ClinicalTrials.gov, identifier NCT0253032 (retrospectively registered on 21 August 2015). (Source: Targeted Oncology)
Source: Targeted Oncology - October 5, 2020 Category: Cancer & Oncology Source Type: research

Targeting TAM to Tame Pancreatic Cancer
AbstractPancreatic cancer is expected to become the second leading cause of cancer-related death within the next few years. Current therapeutic strategies have limited effectiveness and therefore there is an urgency to develop novel effective therapies. The receptor tyrosine kinase subfamily TAM (Tyro3, Axl, MerTK) is directly implicated in the pathogenesis of the metastatic, chemoresistant, and immunosuppressive phenotype in pancreatic cancer. TAM inhibitors are promising investigational therapies for pancreatic cancer due to their potential to target multiple aspects of pancreatic cancer biology. Specifically, recent mec...
Source: Targeted Oncology - September 28, 2020 Category: Cancer & Oncology Source Type: research

Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G)
AbstractBackgroundPredictive markers for the clinical outcomes of second-line treatment in patients with metastatic colorectal cancer (mCRC) remain unclear.ObjectiveThis retrospective biomarker study was conducted to explore predictive markers for patients withKRAS exon 2 wild-type mCRC who were treated with FOLFIRI plus panitumumab (Pani) or bevacizumab (Bev) in the WJOG6210G trial.Patients and methodsThe associations of early tumor shrinkage (ETS), tumor location, and VEGF-D with progression-free survival (PFS) and overall survival (OS) were analyzed using a Cox proportional hazards model. Spearman ’s correlation c...
Source: Targeted Oncology - September 21, 2020 Category: Cancer & Oncology Source Type: research

Gilteritinib: A Review in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukaemia
AbstractGilteritinib (Xospata®), a next-generation tyrosine kinase inhibitor (TKI), is approved in several countries/regions worldwide for the treatment of relapsed or refractory acute myeloid leukaemia (AML) in adults with FMS-like tyrosine kinase 3 (FLT3) mutations. In this patient population, oral gilteritinib significantly improved overall survival (OS) and the response rate for complete remission with full or partial haematological recovery compared with salvage chemotherapy in the phase III ADMIRAL trial. In an integrated safety analysis of patients with relapsed or refractory AML, the most commonly reported grad...
Source: Targeted Oncology - September 16, 2020 Category: Cancer & Oncology Source Type: research

Applying Precision to the Management of BRAF-Mutant Metastatic Colorectal Cancer
AbstractIdentifying the presence or absence of aBRAFV600E mutation is paramount for the management of patients with metastatic colorectal cancer (mCRC) as there are distinct predictive and prognostic implications, as well as unique therapeutic approaches for this molecular subtype. Traditional cytotoxic doublet chemotherapy has historically been ineffective for this poor prognostic group, thereby highlighting the critical need for novel targeted therapies to drive management. Unlike the early success achieved with BRAF-inhibitor monotherapy for patients withBRAFV600E-mutated metastatic melanoma, response rates were found t...
Source: Targeted Oncology - September 4, 2020 Category: Cancer & Oncology Source Type: research

Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis
ConclusionOur study highlighted and confirmed the efficacy of crizotinib in patients with NSCLC withROS1 orMET genetic alterations. Crizotinib had remarkable effects on advanced NSCLC withROS1 fusion, as previously reported. However, the role of this targeted therapy inMET-altered NSCLC remains investigational. (Source: Targeted Oncology)
Source: Targeted Oncology - August 30, 2020 Category: Cancer & Oncology Source Type: research

Correction to: Cabozantinib After a Previous Immune Checkpoint Inhibitor in Metastatic Renal Cell Carcinoma: A Retrospective Multi-Institutional Analysis
While typesetting the article the Table 3 column/row entries are interchanged. Please find below the updated Table (Source: Targeted Oncology)
Source: Targeted Oncology - August 27, 2020 Category: Cancer & Oncology Source Type: research

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features
ConclusionPonatinib seems to target CML progenitor/stem cells better than imatinib. (Source: Targeted Oncology)
Source: Targeted Oncology - August 10, 2020 Category: Cancer & Oncology Source Type: research

Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer
ConclusionsThe results demonstrate that a carefully designed medium size gene panel is as effective as a large panel for the detection of clinically actionable variants and can be run by most molecular pathology laboratories. (Source: Targeted Oncology)
Source: Targeted Oncology - August 7, 2020 Category: Cancer & Oncology Source Type: research